Terasaki Institute For Biomedical Innovation
Los Angeles, CA Doing business as Terasaki Research Institute
- UEI
- Q3SPRLFLMS73
- CAGE
- 7LQN1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 21100 Erwin St, Woodland Hills, CA 91367, USA
- Website
- terasaki.org
- Founded
- 2001
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Terasaki Institute For Biomedical Innovation
Terasaki Institute For Biomedical Innovation, doing business as Terasaki Research Institute, is a nonprofit biomedical research organization based in Woodland Hills, California that receives federal grants as a prime recipient and subrecipient for organ-on-a-chip platform development and advanced biomaterial engineering from the National Institutes of Health. The institute operates exclusively within the federal grant portfolio rather than federal contracting; it does not hold any federal contract vehicles or contract prime awards.
The institute's federal footprint concentrates on grant-funded research in microfluidic organ-on-a-chip systems, biomaterial design, and immunomodulation therapies. As a prime grant recipient, Terasaki leads research into vascularized organ-on-chip platforms modeling human immune responses and allograft rejection mechanisms. Representative prime grant work includes a $6.13 million National Institute of Diabetes and Digestive and Kidney Diseases award (CFDA 93.847) through May 2029 for development of engineered metabolite-based nanoparticles to modulate macrophage polarization in obesity treatment; a $492,250 National Institute of Allergy and Infectious Diseases award (CFDA 93.855) through January 2028 for a vascularized porcine liver on-a-chip platform modeling human xenoimmune responses; a January 2024 National Institute of Biomedical Imaging and Bioengineering award through December 2025 for a vascularized liver-on-a-chip modeling allograft rejection and tolerance; and a July 2023 NIDDK award through June 2028 for engineered nanofibrous microsphere-integrated hydrogel wound dressing platform development for diabetic wounds.
Customer concentration sits entirely within the National Institutes of Health (HHS). The National Institute of Diabetes and Digestive and Kidney Diseases leads by award count (five awards) and the National Cancer Institute by potential value ($43 thousand combined across four awards), with the NIH Office of the Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Allergy and Infectious Diseases rounding out the active set, accounting for 76% of recent awards. The institute operates as a subrecipient on grant work from Mayo Clinic Arizona, University of Texas at Austin, and UCLA, where Terasaki develops organ-on-chip components, biomaterial platforms, and microfluidic delivery systems. Recent sub-award work includes participation in Mayo's drug-eluting biomaterial platform development (July 2024 and July 2025), UCLA's multiple organ-on-chip platform integrating blood-brain barrier and liver chip components (December 2023 and January 2025), and UT Austin's robotic surgical bioprinting system for volumetric muscle loss (February 2023, February 2024, and February 2025). Three awards face ultimate completion within the next twenty-four months. Activity has grown from one award in 2020 to four awards each in 2023, 2024, and 2025.
Quick answers
What is Terasaki Institute For Biomedical Innovation's UEI?
Terasaki Institute For Biomedical Innovation's Unique Entity ID (UEI) in SAM.gov is Q3SPRLFLMS73.
What is Terasaki Institute For Biomedical Innovation's CAGE code?
Terasaki Institute For Biomedical Innovation's CAGE code is 7LQN1.
What is Terasaki Institute For Biomedical Innovation's primary NAICS code?
Terasaki Institute For Biomedical Innovation's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Terasaki Institute For Biomedical Innovation located?
Terasaki Institute For Biomedical Innovation's physical address in SAM.gov is 21100 Erwin St, Woodland Hills, CA 91367, USA.
Is Terasaki Institute For Biomedical Innovation registered in SAM.gov?
Yes. Terasaki Institute For Biomedical Innovation's SAM.gov registration is active through August 18, 2027.
What is Terasaki Institute For Biomedical Innovation's most recent federal award?
Terasaki Institute For Biomedical Innovation's most recent federal grant award is Immunomodulatory nanofibrous modular aerogels for chronic wound healing - project summary chronic wounds (CWS) affect… (R01GM164582), from National Institute of General Medical Sciences, on September 5, 2026.
On GovTribe
See Terasaki Institute For Biomedical Innovation's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors